Kane Biotech Secures $800K to Accelerate Revyve Wound Portfolio
Summary: Kane Biotech (TSX-V: KNE) launches non-brokered private placement: up to 16M shares at $0.05 for $800K gross, closing ~Dec 17, 2025. Funds support working capital, advancing Revyve line against biofilms (key to resistance/poor healing). Gel/Spray FDA-cleared/Health Canada-approved; Cleanser submitted Sep 2025 (pending). Insiders may join; shares hold 4+ months. Stock at $0.035 (52-wk: $0.03–0.13). Bolsters chronic wound solutions amid rising biofilm challenges.
Key Highlights:
- Funding: $800K (16M shares @ $0.05); close Dec 17, 2025.
- Portfolio: Revyve Gel/Spray cleared; Cleanser pending FDA.
- Target: Microbial biofilms in chronic wounds.
- Stock: $0.035 (Nov 27 close); insiders participating.
- Authors: Kane Biotech Inc. (announcement).
Keywords: Kane Biotech, Revyve, biofilm, private placement, wound gel, antibiotic resistance